manufactured by Frosst Iberica,
Sponsors
International Bio Service Co., Ltd., International Bio Service Co. Ltd., International Bio Service Co.,Ltd, Polipharm Co., Ltd.
Conditions
Bioequivalence Study,Bioequivalence studyBioequivalence study,
Phase 1
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Etoricoxib 120 mg Film-coated Tablets and Reference Product (ARCOXIA, Frosst Iberica, S.A., Spain) in Healthy Thai Volunteers under Fasting Conditions
Active, not recruitingTCTR20180124005
Start: 2018-03-02Updated: 2026-03-30
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Etoricoxib 120 mg Film-coated Tablets and Reference Product (ARCOXIA) in Healthy Thai Volunteers under Fasting Conditions
Active, not recruitingTCTR20180424001
Start: 2018-06-25Updated: 2026-03-30
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Etoricoxib Tablets 120 mg and Reference Product (ARCOXIA 120 mg) in Healthy Thai Volunteers under Fasting Conditions
Active, not recruitingTCTR20180925005
Start: 2018-12-16Target: 28Updated: 2026-03-30
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Etoricoxib 90 mg Film-coated Tablets and Reference Product (ARCOXIA) in Healthy Thai Volunteers under Fasting Conditions
Active, not recruitingTCTR20190125005
Start: 2019-03-04Target: 28Updated: 2026-03-30